Cellectar Biosciences Inc.(CLRB)_个股概要_股票价格_最新资讯_行情走势_历史数据

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

CLRB Cellectar Biosciences Inc.

盘后交易 04-26 17:48:55 EDT

3.03

+0.01

+0.33%

盘后3.11

+0.08+2.64%

16:10 EDT

最高3.12	最低2.98	成交量68.66万
今开3.04	昨收3.02	日振幅4.64%
总市值9,775万	流通市值7,459万	总股本3,226万
成交额208.50万	换手率2.79%	流通股本2,462万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"CLRB","market":"US","secType":"STK","nameCN":"Cellectar Biosciences Inc.","latestPrice":3.03,"timestamp":1714161600000,"preClose":3.02,"halted":0,"volume":686577,"hourTrading":{"tag":"盘后","latestPrice":3.11,"preClose":3.03,"latestTime":"16:10 EDT","volume":714,"amount":2168.455128,"timestamp":1714162205270},"delay":0,"floatShares":24616882,"shares":32260510,"eps":-3.107906,"marketStatus":"盘后交易","marketStatusCode":4,"change":0.01,"latestTime":"04-26 17:48:55 EDT","open":3.04,"high":3.12,"low":2.98,"amount":2085040.219293,"amplitude":0.046358,"askPrice":3.12,"askSize":2,"bidPrice":3,"bidSize":5543,"shortable":3,"etf":0,"ttmEps":-3.107906,"exchange":"NASDAQ","tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1714176000000},"adr":0,"adjPreClose":3.02,"adrRate":0,"preHourTrading":{"tag":"盘前","latestPrice":3.02,"preClose":3.02,"latestTime":"09:16 EDT","volume":171,"amount":519.5649978,"timestamp":1714137378540},"postHourTrading":{"tag":"盘后","latestPrice":3.11,"preClose":3.03,"latestTime":"16:10 EDT","volume":714,"amount":2168.455128,"timestamp":1714162205270},"volumeRatio":0.797078},"requestUrl":"/m/hq/s/CLRB?invite=TIGER026","defaultTab":"news","newsList":[{"id":"2428510281","title":"Cellectar Biosciences, Inc.盘中异动 下午盘急速下跌5.30%","url":"https://stock-news.laohu8.com/highlight/detail?id=2428510281","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2428510281?lang=zh_cn&edition=full","pubTime":"2024-04-19 01:32","pubTimestamp":1713461538,"startTime":"0","endTime":"0","summary":"北京时间2024年04月19日01时32分，Cellectar Biosciences, Inc.股票出现异动，股价快速下挫5.30%。Cellectar Biosciences, Inc.股票所在的生物技术行业中，整体跌幅为0.62%。其相关个股中，Bio-Path Holdings, Inc.、Ocean Biomedical Inc C/Wts 14/02/2028 、Conduit Pharmaceuticals Inc C/Wts 22/09/2028涨幅较大，Bio-Path Holdings, Inc.、Benitec Biopharma Inc.、Soligenix, Inc.较为活跃，换手率分别为9862.97%、106.97%、43.19%，振幅较大的相关个股有Bio-Path Holdings, Inc.、Rocket Pharmaceuticals Inc C/Wts 02/09/2026 、Aileron Therapeutics, Inc.，振幅分别为86.72%、73.93%、68.47%。Cellectar Biosciences, Inc.公司简介：Cellectar Biosciences Inc 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240419013218792196c1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240419013218792196c1&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2427388003","title":"Cellectar Biosciences, Inc.盘中异动 下午盘股价大跌5.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2427388003","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2427388003?lang=zh_cn&edition=full","pubTime":"2024-04-16 03:11","pubTimestamp":1713208302,"startTime":"0","endTime":"0","summary":"北京时间2024年04月16日03时11分，Cellectar Biosciences, Inc.股票出现波动，股价大幅跳水5.10%。Cellectar Biosciences, Inc.股票所在的生物技术行业中，整体跌幅为0.56%。其相关个股中，Cingulate Inc C/Wts 10/12/2026 、安皮奥制药、Longeveron Inc.涨幅较大，Longeveron Inc.、Soligenix, Inc.、Allarity Therapeutics, Inc.较为活跃，换手率分别为1579.11%、1244.68%、879.83%，振幅较大的相关个股有安皮奥制药、Soligenix, Inc.、Cassava Sciences Inc C/Wts 15/11/2024，振幅分别为273.33%、117.12%、80.04%。Cellectar Biosciences, Inc.公司简介：Cellectar Biosciences Inc是一家处于临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404160311427920a702&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404160311427920a702&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2427561751","title":"Cellectar Biosciences, Inc.盘中异动 下午盘急速下跌5.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2427561751","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2427561751?lang=zh_cn&edition=full","pubTime":"2024-04-13 02:51","pubTimestamp":1712947919,"startTime":"0","endTime":"0","summary":"北京时间2024年04月13日02时51分，Cellectar Biosciences, Inc.股票出现异动，股价快速下跌5.12%。Cellectar Biosciences, Inc.股票所在的生物技术行业中，整体跌幅为1.52%。Cellectar Biosciences, Inc.公司简介：Cellectar Biosciences Inc是一家处于临床阶段的生物制药公司。其领先的PDC治疗，iopofosine是一种小分子PDC，旨在提供碘-131直接靶向传输到癌细胞，同时限制其暴露于健康细胞。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041302515987e80040&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041302515987e80040&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2426627202","title":"Cellectar Biosciences, Inc.盘中异动 股价大涨5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2426627202","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2426627202?lang=zh_cn&edition=full","pubTime":"2024-04-12 00:07","pubTimestamp":1712851623,"startTime":"0","endTime":"0","summary":"北京时间2024年04月12日00时07分，Cellectar Biosciences, Inc.股票出现异动，股价急速拉升5.01%。Cellectar Biosciences, Inc.股票所在的生物技术行业中，整体跌幅为0.84%。Cellectar Biosciences, Inc.公司简介：Cellectar Biosciences Inc是一家处于临床阶段的生物制药公司。其领先的PDC治疗，iopofosine是一种小分子PDC，旨在提供碘-131直接靶向传输到癌细胞，同时限制其暴露于健康细胞。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240412000703791ff4f1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240412000703791ff4f1&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2426448778","title":"Cellectar Biosciences, Inc.盘中异动 股价大跌5.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2426448778","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2426448778?lang=zh_cn&edition=full","pubTime":"2024-04-11 01:14","pubTimestamp":1712769289,"startTime":"0","endTime":"0","summary":"北京时间2024年04月11日01时14分，Cellectar Biosciences, Inc.股票出现波动，股价大幅下跌5.09%。Cellectar Biosciences, Inc.股票所在的生物技术行业中，整体跌幅为1.28%。其相关个股中，Adial Pharmaceuticals, Inc、Jaguar Health, Inc.、Orgenesis Inc.涨幅较大，Adial Pharmaceuticals, Inc、Silo Pharma, Inc.、Jaguar Health, Inc.较为活跃，换手率分别为1948.44%、76.79%、53.39%，振幅较大的相关个股有Adial Pharmaceuticals, Inc、Orgenesis Inc.、Nutriband Inc C/Wts ，振幅分别为87.61%、74.23%、52.44%。Cellectar Biosciences, Inc.公司简介：Cellectar Biosciences Inc是一家处于临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404110114507a51ed9a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404110114507a51ed9a&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2425341921","title":"Cellectar Biosciences, Inc.盘中异动 股价大跌5.03%报3.78美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2425341921","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2425341921?lang=zh_cn&edition=full","pubTime":"2024-04-05 02:42","pubTimestamp":1712256136,"startTime":"0","endTime":"0","summary":"北京时间2024年04月05日02时42分，Cellectar Biosciences, Inc.股票出现异动，股价急速下跌5.03%。Cellectar Biosciences, Inc.股票所在的生物技术行业中，整体跌幅为0.73%。其相关个股中，Candel Therapeutics, Inc.、Tc Biopharm  Plc C/Wts 10/02/2028 、Tc Biopharm  Plc涨幅较大，Tc Biopharm  Plc、Candel Therapeutics, Inc.、Effector Therapeutics, Inc.较为活跃，换手率分别为3497.50%、317.89%、220.37%，振幅较大的相关个股有Candel Therapeutics, Inc.、Nls Pharmaceutics Ltd C/Wts 02/02/2026、Tc Biopharm  Plc，振幅分别为142.86%、133.46%、111.54%。Cellectar Biosciences, Inc.公司简介：Cellectar Biosciences Inc是一家处于临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240405024217791ecf5f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240405024217791ecf5f&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422920760","title":"Cellectar Biosciences, Inc.2023财年实现净利润-37.98百万美元，同比减少32.80%","url":"https://stock-news.laohu8.com/highlight/detail?id=2422920760","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2422920760?lang=zh_cn&edition=full","pubTime":"2024-03-28 06:13","pubTimestamp":1711577595,"startTime":"0","endTime":"0","summary":"12月31日，Cellectar Biosciences, Inc.公布财报，公告显示公司2023财年净利润为-37.98百万美元，同比减少32.80%；其中营业收入为0.00美元，每股基本收益为-3.11美元。从资产负债表来看，Cellectar Biosciences, Inc.总负债13.43百万美元，其中短期债务58979.00美元，资产负债比为0.90，流动比率为0.81。机构评级：截至2023年12月31日，当前有4家机构对Cellectar Biosciences, Inc.目标价做出预测，其中目标均价为14.75美元，其中最低目标价为7.00美元，最高目标价为28.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403280613218b6b1a72&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403280613218b6b1a72&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2422499293","title":"Cellectar 生物科学公司公布截至 12 月的季度业绩 - 收益摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2422499293","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2422499293?lang=zh_cn&edition=full","pubTime":"2024-03-27 21:31","pubTimestamp":1711546273,"startTime":"0","endTime":"0","summary":"   * Cellectar Biosciences Inc   报告，截至12月底的季度调整后每股亏损61美分，低于去年同期的每股收益-55美分。四位分析师对该季度的平均预期是每股亏损 57 美分。华尔街的预期在每股-78美分到-39美分之间。* Cellectar Biosciences Inc 报告的季度每股收益为亏损 61 美分。* 公司当季亏损 745 万美元。* Cellectar Biosciences Inc 的股价本季度上涨了 39.0%。* 医药同行的平均一致建议是 \"买入\"。华尔街对 Cellectar Biosciences Inc 的 12 个月目标价中位数为 12.00 美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2422751148","title":"Cellectar Biosciences Inc    预计每股亏损 57 美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2422751148","media":"Reuters","top":-1,"share":"https://www.laohu8.com/m/news/2422751148?lang=zh_cn&edition=full","pubTime":"2024-03-25 20:41","pubTimestamp":1711370503,"startTime":"0","endTime":"0","summary":"   * Cellectar Biosciences Inc    将于3月27日公布截至2023年12月31日的财报，预计该公司的季度收入将保持不变。*    * LSEG分析师对Cellectar Biosciences Inc的平均预期是每股亏损57美分。* 华尔街对 Cellectar Biosciences Inc 的 12 个月目标价中位数为 12.00 美元，高于其最新收盘价 4.05 美元。3月25日 - 上一季度业绩。除非另有说明，否则所有数据均以美元为单位。(如对本报告中的数据有任何疑问，请联系 Estimates.Support@lseg.com。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2421318828","title":"Cellectar Biosciences, Inc.盘中异动 股价大涨5.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2421318828","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2421318828?lang=zh_cn&edition=full","pubTime":"2024-03-23 01:29","pubTimestamp":1711128557,"startTime":"0","endTime":"0","summary":"北京时间2024年03月23日01时29分，Cellectar Biosciences, Inc.股票出现波动，股价急速拉升5.17%。Cellectar Biosciences, Inc.股票所在的生物技术行业中，整体跌幅为0.09%。Cellectar Biosciences, Inc.公司简介：Cellectar Biosciences Inc是一家处于临床阶段的生物制药公司。其领先的PDC治疗，iopofosine是一种小分子PDC，旨在提供碘-131直接靶向传输到癌细胞，同时限制其暴露于健康细胞。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403230129177a4e8e84&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403230129177a4e8e84&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2420222950","title":"Cellectar Biosciences, Inc.盘中异动 股价大涨8.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2420222950","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2420222950?lang=zh_cn&edition=full","pubTime":"2024-03-19 21:31","pubTimestamp":1710855096,"startTime":"0","endTime":"0","summary":"北京时间2024年03月19日21时31分，Cellectar Biosciences, Inc.股票出现异动，股价快速拉升8.36%。Cellectar Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.05%。其相关个股中，Fusion Pharmaceuticals Inc.、Enveric Biosciences, Inc.、Hoth Therapeutics, Inc.涨幅较大，Enveric Biosciences, Inc.、Hoth Therapeutics, Inc.、Clearmind Medicine Inc.较为活跃，换手率分别为432.74%、142.24%、117.41%，振幅较大的相关个股有Enveric Biosciences, Inc.、Salarius Pharmaceuticals, Inc.、Lantern Pharma Inc.，振幅分别为17.27%、11.59%、11.23%。Cellectar Biosciences, Inc.公司简介：Cellectar Biosciences Inc是一家处于临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403192131368b4801aa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202403192131368b4801aa&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2417244264","title":"Cellectar Biosciences, Inc.盘中异动 临近收盘股价大跌5.13%报4.02美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2417244264","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2417244264?lang=zh_cn&edition=full","pubTime":"2024-03-06 04:38","pubTimestamp":1709671139,"startTime":"0","endTime":"0","summary":"北京时间2024年03月06日04时38分，Cellectar Biosciences, Inc.股票出现异动，股价急速下跌5.13%。Cellectar Biosciences, Inc.股票所在的生物技术行业中，整体跌幅为1.51%。Cellectar Biosciences, Inc.公司简介：Cellectar Biosciences Inc是一家处于临床阶段的生物制药公司。其领先的PDC治疗，iopofosine是一种小分子PDC，旨在提供碘-131直接靶向传输到癌细胞，同时限制其暴露于健康细胞。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024030604385987e7627c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024030604385987e7627c&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2416623997","title":"Cellectar Biosciences, Inc.盘中异动 早盘大幅拉升5.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2416623997","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2416623997?lang=zh_cn&edition=full","pubTime":"2024-03-02 00:19","pubTimestamp":1709309979,"startTime":"0","endTime":"0","summary":"北京时间2024年03月02日00时19分，Cellectar Biosciences, Inc.股票出现波动，股价快速上涨5.10%。Cellectar Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为2.44%。其相关个股中，Biovie Inc.、Adial Pharmaceuticals, Inc、Cardiff Oncology, Inc.涨幅较大，Adial Pharmaceuticals, Inc、Enveric Biosciences, Inc.、Jaguar Health, Inc.较为活跃，换手率分别为3701.97%、401.88%、335.05%，振幅较大的相关个股有Biovie Inc.、Pasithea Therapeutics Corp C/Wts 12/08/2026 、Jaguar Health, Inc.，振幅分别为96.77%、81.48%、81.19%。Cellectar Biosciences, Inc.公司简介：Cellectar Biosciences Inc是一家处于临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240302001940861da998&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240302001940861da998&s=b","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cellectar.com","stockEarnings":[{"period":"1week","weight":-0.0066},{"period":"1month","weight":-0.2156},{"period":"3month","weight":-0.1947},{"period":"6month","weight":0.2851},{"period":"1year","weight":1.0671},{"period":"ytd","weight":0.0903}],"compareEarnings":[{"period":"1week","weight":0.0079},{"period":"1month","weight":-0.0295},{"period":"3month","weight":0.033},{"period":"6month","weight":0.226},{"period":"1year","weight":0.2452},{"period":"ytd","weight":0.0593}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Cellectar Biosciences, Inc.以前名为Novelos Therapeutics, Inc.于1996年6月成立于特拉华州。2014年2月11日，公司更名为现在的名字。它是一家生物制药公司，开发用于治疗肿瘤成像化合物。该公司的癌症靶向技术允许选择性递送的多种剂对癌症细胞，包括癌症干细胞。该公司目前正在开发三种专利的候选产品：I-124-CLR1404 是一种小分子，广谱，肿瘤的靶向性的正电子发射断层扫描（PET）显像剂，该公司认为其必须在范围广泛的癌症肿瘤和转移的选择性检测的第一种可能。I-131-CLR1404是一种小分子，广谱，癌靶向分子放射治疗的直接和选择性地提供细胞毒性（细胞杀伤）辐射到癌细胞和癌干细胞。CLR1502是一种临床前，小分子，肿瘤靶向，非放射性的光学成像术中肿瘤边缘照明和非侵入性的肿瘤成像剂。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":0.027916},{"month":2,"riseRate":0.6,"avgChangeRate":0.012926},{"month":3,"riseRate":0.5,"avgChangeRate":-0.02847},{"month":4,"riseRate":0.2,"avgChangeRate":-0.097085},{"month":5,"riseRate":0.333333,"avgChangeRate":0.052545},{"month":6,"riseRate":0.444444,"avgChangeRate":-0.058603},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.066667},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.019682},{"month":9,"riseRate":0.4,"avgChangeRate":-0.041969},{"month":10,"riseRate":0.1,"avgChangeRate":-0.147573},{"month":11,"riseRate":0.4,"avgChangeRate":-0.05683},{"month":12,"riseRate":0.4,"avgChangeRate":0.02288}],"exchange":"NASDAQ","name":"Cellectar Biosciences Inc.","nameEN":"Cellectar Biosciences"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Cellectar Biosciences Inc.(CLRB)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Cellectar Biosciences Inc.(CLRB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Cellectar Biosciences Inc.,CLRB,Cellectar Biosciences Inc.股票,Cellectar Biosciences Inc.股票老虎,Cellectar Biosciences Inc.股票老虎国际,Cellectar Biosciences Inc.行情,Cellectar Biosciences Inc.股票行情,Cellectar Biosciences Inc.股价,Cellectar Biosciences Inc.股市,Cellectar Biosciences Inc.股票价格,Cellectar Biosciences Inc.股票交易,Cellectar Biosciences Inc.股票购买,Cellectar Biosciences Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Cellectar Biosciences Inc.(CLRB)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Cellectar Biosciences Inc.(CLRB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}

公司概况